Pathogenesis and Novel Therapeutic Targets of Fatty Liver Disease and Cancer
Pathogenesis and Novel Therapeutic Targets of Fatty Liver Disease and Cancer
批准号:
10918948
负责人:
bin gao
金额:
$136.71万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAdenosineAdenovirusesAgingAlcoholic HepatitisAlcoholic Liver DiseasesAngiogenesis InhibitionBioinformaticsCarbon TetrachlorideCellsChronicDataDevelopmentDiethylnitrosamineEnvironmentEthanol MetabolismGene DeliveryGeneticGoalsHypoxiaImmuneImmunologicsImmunosuppressionIn VitroInfiltrationInflammationInflammatoryInjectionsKnockout MiceLaboratoriesMacrophageMalignant Epithelial CellMalignant neoplasm of liverMediatingMicroRNAsMusMyeloid CellsPD-1/PD-L1PathogenesisPathway interactionsPlayPrimary carcinoma of the liver cellsRNA analysisRegimenRoleT-LymphocyteTherapeuticWild Type Mouseangiogenesisfatty liver diseaseimplantationin vivoliver cancer modelliver inflammationmicroRNA deliverymouse modelneoplastic cellneutrophilnew therapeutic targetpatient subsetsprogrammed cell death ligand 1programmed cell death protein 1transcriptome sequencingtumortumor hypoxiatumor microenvironmenttumorigenesis
中文摘要
我们实验室一直积极研究酒精相关性肝病的发病机制,重点研究酒精相关性肝炎和肝癌的炎症细胞特征。我们发现了miR-223,这是一种在酒精相关肝脏疾病中高度升高的miRNA,在调节肿瘤环境和肝癌发展中起重要作用。
英文摘要
Our laboratory has been actively studying the pathogenesis of alcohol-associated liver disease, focusing on characterization of inflammatory cells in alcohol-associated hepatitis and liver cancer. we have identified miR-223, a miRNA that is highly elevated in alcohol-associated liver disease, and plays an important role in regulating tumor environment and liver cancer development.
The current treatment for hepatocellular carcinoma (HCC) to block angiogenesis and immunosuppression provides some benefits only for a subset of patients with HCC, thus optimized therapeutic regimens are unmet needs. Addressing these needs require a thorough understanding of the underlying mechanisms by which tumor cells orchestrate an inflamed tumor microenvironment with significant myeloid cell infiltration. MicroRNA-223 (miR-223) is highly expressed in myeloid cells but its role in regulating tumor microenvironment remains unknown. Wild-type and miR-223 knockout mice were subjected to two mouse models of inflammation-associated HCC induced by injection of diethylnitrosamine (DEN) or orthotopic HCC cell implantation in chronic carbon tetrachloride (CCl4)-treated mice. Genetic deletion of miR-223 markedly exacerbated tumorigenesis in inflammation-associated HCC. Compared with wild-type mice, miR-223 knockout mice had more infiltrated programmed cell death 1 (PD-1+) T cells and programmed cell death ligand 1 (PD-L1+) macrophages after DEN+CCl4 administration. Bioinformatic analyses of RNA sequencing data revealed a strong correlation between miR-223 levels and tumor hypoxia, a condition that is well-documented to regulate PD-1/PD-L1. In vivo and in vitro mechanistic studies demonstrated that miR-223 did not directly target PD-1 and PD-L1 in immune cells. Rather, it indirectly downregulated them by modulating tumor microenvironment via the suppression of ha ypoxia-inducible factor 1-driven CD39/CD73-adenosine pathway in HCC. Moreover, gene delivery of miR-223 via adenovirus inhibited angiogenesis and hypoxia-mediated PD-1/PD-L1 activation in both HCC models, thereby hindering HCC progression. The miR-223 plays a critical role in modulating hypoxia-induced tumor immunosuppression and angiogenesis, which may serve as a novel therapeutic target for HCC.
期刊论文(49)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/hep.24517
发表时间:
2011-09-02
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
[Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B]
通讯作者:
Gao B
DOI:
10.1111/j.1440-1746.2011.07003.x
发表时间:
2012-03
期刊:
Journal of gastroenterology and hepatology
影响因子:
4.1
作者:
[Gao B]
通讯作者:
Gao B
DOI:
10.1002/hep4.1145
发表时间:
2018-03
期刊:
Hepatology communications
影响因子:
5.1
作者:
[Guillot A, Gasmi I, Brouillet A, Ait-Ahmed Y, Calderaro J, Ruiz I, Gao B, Lotersztajn S, Pawlotsky JM, Lafdil F]
通讯作者:
Lafdil F
DOI:
10.1002/hep.27406
发表时间:
2014-12
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
[Wang FS, Fan JG, Zhang Z, Gao B, Wang HY]
通讯作者:
Wang HY
Reply to Brewer: Liver-targeted ALDH2 inhibition may reduce alcohol-seeking behaviors with limited side effects.
回复 Brewer:肝脏靶向 ALDH2 抑制可能会减少酗酒行为,且副作用有限。
DOI:
10.1073/pnas.2001049117
发表时间:
2020
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Guillot,Adrien, Koob,GeorgeF, Gao,Bin]
通讯作者:
Gao,Bin
共 33 条
ETHANOL AND IL6 SIGNAL TRANSDUCTION
-
批准号:2894248
-
项目类别:
-
资助金额:$7.25万
-
财政年份:1998
-
负责人:bin gao
-
依托单位:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
-
批准号:2633945
-
项目类别:
-
资助金额:$10.13万
-
财政年份:1998
-
负责人:bin gao
-
依托单位:
ETHANOL AND IL6 SIGNAL TRANSDUCTION
-
批准号:2558838
-
项目类别:
-
资助金额:$7.25万
-
财政年份:1998
-
负责人:bin gao
-
依托单位:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
-
批准号:6172833
-
项目类别:
-
资助金额:$9.9万
-
财政年份:1998
-
负责人:bin gao
-
依托单位:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
-
批准号:2895764
-
项目类别:
-
资助金额:$9.61万
-
财政年份:1998
-
负责人:bin gao
-
依托单位:
Innate immunity and cytokines in liver disease
-
批准号:8148175
-
项目类别:
-
资助金额:$82.28万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Mechanisms of Alcoholic Liver Disease
-
批准号:7591944
-
项目类别:
-
资助金额:$60.01万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Molecular Mechanism For Resistance To Interferon Therapy
-
批准号:6675119
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Immunologic Mechanisms of Alcoholic Liver Disease
-
批准号:8746472
-
项目类别:
-
资助金额:$88.82万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Mechanisms of Alcoholic Liver Disease
-
批准号:7963847
-
项目类别:
-
资助金额:$64.96万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Biological Significance and Therapeutic Potential of Cyt
-
批准号:6818687
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Pathogenesis and Novel Therapeutic Targets of Fatty Liver Disease and Cancer
-
批准号:10004417
-
项目类别:
-
资助金额:$111.62万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Mechanisms of Alcoholic Liver Disease
-
批准号:7146675
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Innate immunity and cytokines in liver diseases
-
批准号:8344683
-
项目类别:
-
资助金额:$109.67万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Pathogenesis and Novel Therapeutic Targets of Fatty Liver Disease and Cancer
-
批准号:10701535
-
项目类别:
-
资助金额:$131.31万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Molecular Mechanism For The Antiviral And Antitumor Acti
-
批准号:6675116
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Synergistic Effect Of Alcohol And Viral Hepatitis On Liv
-
批准号:6675120
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Biological Significance and Therapeutic Potential of Cyt
-
批准号:6983166
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Immunity, liver injury and repair
-
批准号:7732123
-
项目类别:
-
资助金额:$37.39万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
Molecular mechanisms of liver injury, repair, and immunity
-
批准号:10004416
-
项目类别:
-
资助金额:$111.62万
-
财政年份:--
-
负责人:bin gao
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: